Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Search
  • 302 A phase I trial of intratu...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma

302 A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma

Bibliographic Details
Main Authors: Matthias Gromeier, Georgia Beasley, Nellie Farrow, Karenia Landa, Maria Angelica Seilm, Sin-Ho Jung, Darell Bigner, Andrea True Kelly, Smita Nair, April Salama
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
    by: Matthias Gromeier, et al.
    Published: (2021-04-01)
  • Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
    by: Eda K. Holl, et al.
    Published: (2019-07-01)
  • An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect
    by: Cho Rong Hong, et al.
    Published: (2019-02-01)
  • Overall Survival Improved for Contemporary Patients with Melanoma: A 2004–2015 National Cancer Database Analysis
    by: Norma E. Farrow, et al.
    Published: (2020-05-01)
  • Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
    by: Andrew J. Brenner, et al.
    Published: (2021-01-01)

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...